The Evolution of HTA in Emerging Markets Health-Care ... - TREE
The Evolution of HTA in Emerging Markets Health-Care ... - TREE
The Evolution of HTA in Emerging Markets Health-Care ... - TREE
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
OHE Consult<strong>in</strong>g Report for PhRMA<br />
5 January 2011<br />
<strong>The</strong> sort <strong>of</strong> <strong>HTA</strong> processes which are suggested may be different <strong>in</strong> each case, depend<strong>in</strong>g on the<br />
particular issues evident <strong>in</strong> the health care system. For example, <strong>in</strong> Brazil, the cost-‐effectiveness <strong>of</strong><br />
services is relevant to address<strong>in</strong>g resource allocation <strong>in</strong> the public system and <strong>in</strong> provid<strong>in</strong>g a basis for<br />
modify<strong>in</strong>g expectations about entitlement to care. In contrast, <strong>in</strong> Ch<strong>in</strong>a the pr<strong>in</strong>cipal requirement is<br />
for cl<strong>in</strong>ical protocols to manage chronic disease and to assist <strong>in</strong> counter<strong>in</strong>g the perverse <strong>in</strong>centives<br />
toward non-‐basic treatments.<br />
Lesson 3: ‘One size fits all’ <strong>HTA</strong> processes and methods are unlikely to be appropriate for emerg<strong>in</strong>g<br />
markets. <strong>The</strong>re needs to be clarity over the purpose <strong>of</strong> <strong>HTA</strong> – and the methods and processes which<br />
are adopted need to be fit for purpose.<br />
<br />
<br />
<br />
<strong>HTA</strong> is not an objective ‘tool kit’ that is transferable to any sett<strong>in</strong>g.<br />
“Value” <strong>of</strong> new drugs varies, and is subjective and based on local preferences and other<br />
values.<br />
Real value depends <strong>in</strong> a “second-‐best” world on the match between costs and the value <strong>of</strong><br />
all other <strong>in</strong>puts (hospitals, physician, nurses, equipment, etc.).<br />
In particular, it is important to give careful thought to the way <strong>in</strong> which <strong>HTA</strong> processes work<br />
alongside the pric<strong>in</strong>g and reimbursement systems for health care technologies – which <strong>in</strong> turn are<br />
part <strong>of</strong> the wider health system ‘architecture’ <strong>in</strong> each country. <strong>HTA</strong> processes may need to be<br />
tailored to meet the particular means by which pric<strong>in</strong>g regulations work <strong>in</strong> each country. <strong>The</strong><br />
outcomes <strong>of</strong> the health care system, for patients and the public, will be a product <strong>of</strong> both. Both<br />
reference pric<strong>in</strong>g and <strong>HTA</strong> represent ways <strong>of</strong> obta<strong>in</strong><strong>in</strong>g value for money from new health care<br />
technologies. Drummond, et al. (2010) argue that the most efficient approach is likely to comprise a<br />
comb<strong>in</strong>ation <strong>of</strong> these.<br />
Lesson 4: <strong>HTA</strong> and pric<strong>in</strong>g regulations work hand <strong>in</strong> hand: the approach to <strong>HTA</strong> should be appropriate<br />
to, and work sensibly <strong>in</strong> comb<strong>in</strong>ation with, the particular approach to pric<strong>in</strong>g technologies.<br />
For example, <strong>HTA</strong> based on reimbursement levels <strong>in</strong> Taiwan ignores what providers actually have to<br />
pay for new drugs. This would tend to under-‐estimate real-‐world cost-‐effectiveness.<br />
Limits to the lessons that may be drawn<br />
Beyond the broad lessons and <strong>in</strong>sights noted above, there are limits on the ability to draw broad<br />
conclusions from three case studies about the way that health care systems and <strong>HTA</strong> are evolv<strong>in</strong>g <strong>in</strong><br />
emerg<strong>in</strong>g markets.<br />
While the issues we discussed above are common to emerg<strong>in</strong>g markets, many more <strong>of</strong> the<br />
observations about issues evident <strong>in</strong> three countries are specific to the three countries exam<strong>in</strong>ed.<br />
Each has its own particular characteristics <strong>in</strong> terms <strong>of</strong> arrangements for fund<strong>in</strong>g and provision <strong>of</strong><br />
health care, and sits <strong>in</strong> the context <strong>of</strong> a wider economy which also has its own dist<strong>in</strong>ctive<br />
61